NCT00575068 - Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

September 30, 2002

Study Completion Date

November 30, 2010

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG

IDEC-114

Phase 1-A Group 1 - 125 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 2 - 250 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 3 - 375 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-B Group 4 - 500 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase II-A \& II-B - Dosage start at the MTD (up to 375 mg/m2)

Trial Locations (4)

14263

Research Site, Buffalo

27710

Research Site, Durham

55902

Research Site, Rochester

85724

Research Site, Tucson